Oliver Dorigo

Apr 3, 2023 | survivornet.com | Rodrigo Edelmuth |Jonathan S. Berek |Oliver Dorigo |Ursula Matulonis

PARP Inhibitors as Maintenance TherapyPARP inhibitors are a type of targeted cancer drug commonly used as maintenance therapy. Maintenance therapy is a form of treatment that aims to delay the time to a possible recurrence after the patient has already undergone chemotherapy and possibly surgery. A new study underscores value of long-term follow-up after study treatment ends.

Mar 27, 2023 | onclive.com | Oliver Dorigo

Oliver Dorigo, MD, PhD, member, Stanford Cancer Institute; associate professor, obstetrics and gynecologic oncology, Stanford University Medical Center; director, gynecologic oncology fellowship, clinical research group for gynecologic cancer trials, gynecologic oncology clinical care program, Mary Lake Polan Gynecologic Oncology Research Laboratory, and obstetrics and gynecology, Division of Gynecologic Oncology, Stanford Health Care, discusses the clinical efficacy of maveropepimut-S...